Bupropion metabolites and methods of their synthesis and use
CA 2400482 C · Owner: Senanayake, Chrisantha H. · Inventors: Grover, Paul; Fang, Qun K.; Senanayake, Chrisantha H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to sexual dysfunction, affective disorders cerebral function disorders, cigarette smoking and , incontinence. Methods of making optically pure bupropion metabolites are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 23, 2000 and granted October 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 23, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 23, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.